Stay updated on Nivolumab with 5-azacytidine in Childhood AML Clinical Trial
Sign up to get notified when there's something new on the Nivolumab with 5-azacytidine in Childhood AML Clinical Trial page.

Latest updates to the Nivolumab with 5-azacytidine in Childhood AML Clinical Trial page
- Check3 days agoNo Change Detected
- Check4 days agoChange DetectedPage revision updated from v3.3.3 to v3.3.4.SummaryDifference0.1%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedLocations were consolidated into a single 'Locations' section, replacing the previous separate state entries (California, Georgia, Maryland, New York, North Carolina, Ohio, Tennessee, Texas, Utah, Washington). The HHS Vulnerability Disclosure link was removed and the revision label updated to v3.3.3.SummaryDifference1%

- Check54 days agoChange DetectedPage revision updated from v3.2.0 to v3.3.2; no study details or content appear to be changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check61 days agoChange DetectedRemoved the government funding status notice from the page; the banner only conveyed operational status and its removal does not affect the study details or eligibility criteria. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check75 days agoChange DetectedNo substantive changes to the study page content were detected; only minor formatting or layout differences appear in the screenshots.SummaryDifference0.4%

- Check104 days agoChange DetectedNew operating-status notice and version update to v3.2.0; previous v3.1.0 version tag removed.SummaryDifference3%

Stay in the know with updates to Nivolumab with 5-azacytidine in Childhood AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab with 5-azacytidine in Childhood AML Clinical Trial page.